TY - JOUR
TI - Clinical evidence supporting ceftaroline fosamil and ceftobiprole for complicated skin and soft tissue infections
AU - Leventogiannis, K.
AU - Mouktaroudi, M.
AU - Giamarellos-Bourboulis, E.J.
JO - Current Opinion in Infectious Diseases
PY - 2023
VL - 36
TODO - 2
SP - 89-94
PB - Lippincott Williams and Wilkins
SN - 0951-7375, 1473-6527
TODO - 10.1097/QCO.0000000000000900
TODO - ceftaroline fosamil;  ceftobiprole;  antiinfective agent;  ceftaroline;  ceftaroline fosamil;  ceftobiprole;  cephalosporin derivative, antibiotic therapy;  antimicrobial activity;  cost benefit analysis;  diabetic foot;  drug efficacy;  human;  maximum concentration;  methicillin resistant Staphylococcus aureus;  methicillin susceptible Staphylococcus aureus;  MIC90;  minimum inhibitory concentration;  monotherapy;  nonhuman;  Review;  skin infection;  soft tissue infection;  methicillin resistant Staphylococcus aureus;  microbial sensitivity test;  soft tissue infection;  Staphylococcus infection, Anti-Bacterial Agents;  Cephalosporins;  Humans;  Methicillin-Resistant Staphylococcus aureus;  Microbial Sensitivity Tests;  Soft Tissue Infections;  Staphylococcal Infections
TODO - Purpose of review: Ceftaroline and ceftobiprole are advanced generation cephalosporins with activity against methicillin-resistant Staphylococcus aureus (MRSA). This review summarizes their clinical efficacy for complicated skin and soft tissue infections (cSSTIs). Recent findings: Both these agents retain excellent in vitro activity against both MRSA and Gram-negative isolates from patients with CSSTIs. Both these agents are registered for the management of cSSTIs based on the results of large scale phase III noninferiority trials. Ceftaroline and ceftobiprole are noninferior to the combination of vancomycin and aztreonam as this was assessed by their clinical cure rate at the test-of-cure visits. Furthermore, ceftobiprole is noninferior to comparators for the achievement of early clinical success at 72 h. Ceftaroline achieves 81% clinical cure against diabetic foot infections. Summary: Ceftaroline and ceftobiprole can be used as monotherapy for the treatment of cSSTIs. Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
ER -